Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $139.51 million versus the consensus estimate of $79.31 million.

GUIDANCE:

Novavax sees FY2026 revenue of $230-270 million, versus the consensus of $394.3 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.